The following table sets forth the computation of the Company’s basic and diluted net loss per share:


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Numerator:
Net loss	$	(54,799	)	$	(39,480	)	$	(111,536	)	$	(78,762	)
Denominator:
Shares used to compute net loss per share, basic and diluted
Weighted average shares of common stock outstanding		99,280,401			77,539,468			92,728,853			67,476,597
Weighted average shares of pre-funded warrants to purchase common stock		44,408,300			16,600,818			34,114,812			12,840,991
Weighted average shares of common stock outstanding used to compute basic and diluted net loss per share		143,688,701			94,140,286			126,843,665			80,317,588
Net loss per share, basic and diluted	$	(0.38	)	$	(0.42	)	$	(0.88	)	$	(0.98	)

Included within the weighted average shares of common stock outstanding for the three and six months ended June 30, 2026 and 2025 are 44,408,300 and 16,600,818 shares of common stock issuable upon the exercise of pre-funded warrants, respectively. The pre‑funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share.

The following table presents the potentially dilutive securities outstanding as of the dates indicated that were excluded from the computation of diluted net loss per share because the effect of including them would have been anti-dilutive due to the Company’s net loss during the periods presented:


	As of June 30,
	2026		2025
Options to purchase common stock		6,724,162		3,324,305
Nonvested restricted stock units		5,590,513		3,102,124
Nonvested performance stock units		1,689,025		2,074,188
Shares subject to employee stock purchase plan		235,127		216,802
Warrants		2,000		2,563
Total		14,240,827		8,719,982